Statin Side Effects: Muscle, Liver, Diabetes Risk, and Clinical Context

Statins are generally well-tolerated; serious adverse events are rare. Benefit-risk strongly favors use in indicated patients.

Documented Side Effects

• Myopathy: Myalgia (5–10%), myositis (<1%), rhabdomyolysis (0.001%) — CK monitoring if symptomatic
• Liver: Transient ALT/AST elevation (0.5–2%); clinical hepatotoxicity rare. No routine LFT monitoring needed
• New-onset diabetes: NNH ~255 over 4 years (higher intensity, metabolic syndrome). Net CVD benefit outweighs risk
• GI: Nausea, constipation, dyspepsia — usually mild, transient
• Drug interactions: CYP3A4 inhibitors (clarithromycin, azoles, grapefruit) ↑ statin levels; avoid simvastatin/lovastatin with strong inhibitors
• Cognitive: FDA label notes rare memory/confusion reports; RCTs show no causal link; may improve vascular dementia risk
• Sleep: Insomnia/nightmares reported; not consistent in trials

Management

• Switch statin (hydrophilic: rosuvastatin, pravastatin less muscle penetration)
• Reduce dose/frequency (alternate-day)
• CoQ10 (evidence mixed)
• Rule out other causes (hypothyroid, vitamin D deficiency, overexertion)

Do not stop without clinician guidance—ASCVD risk rebounds.